Explore

Rapid Read Rapid Read
Vektor Medical Secures FDA Clearance for Enhanced Cardiac Mapping Technology

Vektor Medical Secures FDA Clearance for Enhanced Cardiac Mapping Technology

Vektor Medical, a company specializing in medical technology, has received FDA 510(k) clearance for its next-generation vMap technology. This clearance allows for expanded non-invasive mapping capabilities, including atrial flutter mapping, direct ECG data streaming, and enhanced connectivity with electroanatomic mapping systems. The vMap technology, now classified as Software as a Medical Device (SaMD), can be implemented without custom hardware, facilitating broader adoption across health systems. The technology processes standard 12-lead ECG data to generate detailed cardiac maps, aiding in the identification and localization of arrhythmia sources. This development is expected to streamline workflows in electrophysiology labs and improve patient outcomes by enabling faster and more accurate arrhythmia analysis.
Rapid Read Rapid Read
Medical Microinstruments Gains FDA Clearance for Robotic Surgical Tools Enhancing Microsurgery Precision

Medical Microinstruments Gains FDA Clearance for Robotic Surgical Tools Enhancing Microsurgery Precision

Medical Microinstruments (MMI) has received FDA 510(k) clearance for its NanoWrist Scissors and Forceps, designed for soft tissue dissection in complex surgeries. These instruments are part of MMI's Symani Surgical System, which aids in procedures requiring extreme precision, such as lymphatic repair and cancer-related reconstructions. The first U.S. clinical use of these tools was conducted at Tampa General Hospital, where they were used in a lymphovenous bypass procedure. The instruments offer advanced features like motion scaling and tremor reduction, enhancing surgical precision beyond human capabilities.
Trendline Trendline
a2z Radiology AI Secures $4.5M to Enhance CT Triage System

a2z Radiology AI Secures $4.5M to Enhance CT Triage System

a2z Radiology AI Secures $4.5M to Enhance CT Triage System
Trendline Trendline
Digital Transformation in Healthcare: Alfred Olivares Discusses Affordability and Innovation

Digital Transformation in Healthcare: Alfred Olivares Discusses Affordability and Innovation

Digital Transformation in Healthcare: Alfred Olivares Discusses Affordability and Innovation
Rapid Read Rapid Read
FDA Approves Flow Neuroscience's At-Home Brain Stimulation Device for Depression Treatment

FDA Approves Flow Neuroscience's At-Home Brain Stimulation Device for Depression Treatment

Flow Neuroscience has received FDA approval for its at-home brain stimulation device, Flow, designed to treat major depressive disorder (MDD). This marks the first time a non-drug therapy for depression can be prescribed for home use in the U.S. The device uses transcranial direct current stimulation (tDCS) to apply a gentle electrical current to the prefrontal cortex, which is often underactive in people with depression. The approval follows a landmark clinical study published in Nature Medicine, demonstrating significant symptom reduction in patients using the device. The study showed that 58% of patients achieved remission by the end of a 10-week period, with the device proving effective even for those already on medication or psychotherapy. Flow's device has been used by over 55,000 people in Europe and is expected to be available in the U.S. by Q2 2026.
Reuters Reuters
Nick Clegg joins VC firm HIRO Capital to target spatial AI opportunities

Nick Clegg joins VC firm HIRO Capital to target spatial AI opportunities

By Paul Sandle LONDON, Dec 10 (Reuters) - Nick Clegg, the former president of global affairs at Meta and deputy prime minister of Britain, has joined founder-led venture capital firm HIRO Capital to invest in spatial AI innovation in Europe, the firm said on Wednesday.
Rapid Read Rapid Read
Robert Stone Honored as Influential Healthcare CEO for Expanding Cancer Care

Robert Stone Honored as Influential Healthcare CEO for Expanding Cancer Care

Robert Stone, CEO of City of Hope, has been recognized as one of the most influential leaders in healthcare by Modern Healthcare and Becker's Hospital Review. Stone's leadership has expanded access to advanced cancer care and research across the U.S., with City of Hope transforming into a national organization. Under his guidance, the organization has launched a national clinical trials network and developed advanced treatments like immunotherapy. Stone's efforts also focus on equitable access to cancer care and workforce development.
Trendline Trendline
WTW to Acquire Newfront in $1.3 Billion Deal to Expand Middle-Market Reach

WTW to Acquire Newfront in $1.3 Billion Deal to Expand Middle-Market Reach

WTW to Acquire Newfront in $1.3 Billion Deal to Expand Middle-Market Reach
Rapid Read Rapid Read
FDA Qualifies PathAI's AIM-MASH Tool, Revolutionizing MASH Clinical Trials

FDA Qualifies PathAI's AIM-MASH Tool, Revolutionizing MASH Clinical Trials

PathAI has achieved a significant milestone with the FDA qualification of its AIM-MASH AI Assist tool, marking it as the first AI-powered pathology biomarker to receive such status under the FDA's Drug Development Tool program. This follows a similar qualification from the European Medicines Agency, establishing AIM-MASH as the first tool with dual U.S. and EU regulatory recognition. The tool addresses variability in MASH clinical trials by standardizing liver biopsy scoring, thus reducing human variability and enabling more accurate enrollment and endpoint assessment.
Trendline Trendline
Genentech Unveils Promising Lunsumio Data for Lymphoma Treatment at Medical Conference

Genentech Unveils Promising Lunsumio Data for Lymphoma Treatment at Medical Conference

Genentech Unveils Promising Lunsumio Data for Lymphoma Treatment at Medical Conference
Trendline Trendline
Arrowhead Pharmaceuticals Achieves Milestones with FDA Approval and Novartis Deal

Arrowhead Pharmaceuticals Achieves Milestones with FDA Approval and Novartis Deal

Arrowhead Pharmaceuticals Achieves Milestones with FDA Approval and Novartis Deal
Reuters Reuters
Oppenheimer sets Street-high 8,100 S&P 500 target for 2026

Oppenheimer sets Street-high 8,100 S&P 500 target for 2026

Dec 8 (Reuters) - Oppenheimer Asset Management on Monday set a year-end 2026 target of 8,100 for the S&P 500 index, the most bullish forecast among major Wall Street brokerages, citing expectations of strong corporate earnings and continued resilience in the U.S. economy.